Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Computation-based drug-repurposing/repositioning approaches can greatly speed up the traditional drug discovery process. To date, systematic and comprehensive computation-based approaches to identify and validate drug-repositioning candidates for epithelial ovarian cancer (EOC) have not been undertaken. Here, we present a novel drug discovery strategy that combines a computational drug-repositioning system (DrugPredict) with biological testing in cell lines in order to rapidly identify novel drug candidates for EOC. DrugPredict exploited unique repositioning opportunities rendered by a vast amount of disease genomics, phenomics, drug treatment, and genetic pathway and uniquely revealed that non-steroidal anti-inflammatories (NSAIDs) rank just as high as currently used ovarian cancer drugs. As epidemiological studies have reported decreased incidence of ovarian cancer associated with regular intake of NSAIDs, we assessed whether NSAIDs could have chemoadjuvant applications in EOC and found that (i) NSAID Indomethacin induces robust cell death in primary patient-derived platinum-sensitive and platinum- resistant ovarian cancer cells and ovarian cancer stem cells and (ii) downregulation of β-catenin is partially driving effects of Indomethacin in cisplatin-resistant cells. In summary, we demonstrate that DrugPredict represents an innovative computational drug- discovery strategy to uncover drugs that are routinely used for other indications that could be effective in treating various cancers, thus introducing a potentially rapid and cost-effective translational opportunity. As NSAIDs are already in routine use in gynecological treatment regimens and have acceptable safety profile, our results will provide with a rationale for testing NSAIDs as potential chemoadjuvants in EOC patient trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
A comparative encyclopedia of DNA elements in the mouse genome
Yue, F., Cheng, Y., Breschi, A., Vierstra, J., Wu, W., Ryba, T., Sandstrom, R., Ma, Z., Davis, C., Pope, B. D., et al. (2014) · Nature · doi:10.1038/nature13992 · Cited by 1,781
Evolution of platinum resistance in high-grade serous ovarian cancer
Cooke, S. L., & Brenton, J. D. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70123-1 · Cited by 213
McGettigan, P., Roderick, P., Mahajan, R., Kadam, A., & Pollock, A. M. (2015) · PLoS Medicine · doi:10.1371/journal.pmed.1001826 · Cited by 59
Cited by
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
Wang, Q., & Xu, R. (2019) · BMC Genomics · doi:10.1186/s12864-019-5510-y · Cited by 46
Self-citationWang, R., Li, S., Cheng, L., Wong, M. H., & Leung, K. S. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-3283-6 · Cited by 37
A Proteotranscriptomic-Based Computational Drug-Repositioning Method for Alzheimer’s Disease
Lee, S. Y., Song, M.-Y., Kim, D., Park, C., Park, D. K., Kim, D. G., Yoo, J. S., & Kim, Y. H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01653 · Cited by 32
“…cancer genomes, and consists of multi-omics data generated by RNA-seq, copy-number variation analysis, genomic mutation, and DNA methylation, generated from 11,000 patients across 33 tumor types, together with relevant clinical information, including list of prescribed drugs (Nagaraj et al., 2018).”
Background
Metadata
- Authors
- Nagaraj, A. B., Wang, Q. Q., Joseph, P., Zheng, C., Chen, Y., Kovalenko, O., Singh, S., Armstrong, A., Resnick, K., Zanotti, K., Waggoner, S., Xu, R., & DiFeo, A.
- Venue
- Oncogene
- Published
- 2017-10-02
- Volume
- 37
- Issue
- 3
- Pages
- 403-414
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2762358889
- Cited by
- 93
- References
- 8
- FWCI
- 7.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. https://app.cochat.ai/papers/10.1038/onc.2017.328
- The paper
- Nagaraj, A. B., Wang, Q. Q., Joseph, P., Zheng, C., Chen, Y., Kovalenko, O., Singh, S., Armstrong, A., Resnick, K., Zanotti, K., Waggoner, S., Xu, R., & DiFeo, A. (2018). Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. Oncogene. https://doi.org/10.1038/onc.2017.328
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.